Your browser doesn't support javascript.
loading
Tumor edge-to-core transition promotes malignancy in primary-to-recurrent glioblastoma progression in a PLAGL1/CD109-mediated mechanism.
Li, Chaoxi; Cho, Hee Jin; Yamashita, Daisuke; Abdelrashid, Moaaz; Chen, Qin; Bastola, Soniya; Chagoya, Gustavo; Elsayed, Galal A; Komarova, Svetlana; Ozaki, Saya; Ohtsuka, Yoshihiro; Kunieda, Takeharu; Kornblum, Harley I; Kondo, Toru; Nam, Do-Hyun; Nakano, Ichiro.
Afiliação
  • Li C; Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cho HJ; Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.
  • Yamashita D; Institute for Refractory Cancer Research, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Abdelrashid M; Department of Neurosurgery, Ehime University, Japan.
  • Chen Q; Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Bastola S; Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Chagoya G; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Elsayed GA; Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Komarova S; Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Ozaki S; Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Ohtsuka Y; Department of Neurosurgery, Ehime University, Japan.
  • Kunieda T; Department of Neurosurgery, Ehime University, Japan.
  • Kornblum HI; Department of Neurosurgery, Ehime University, Japan.
  • Kondo T; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Nam DH; Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Nakano I; Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Neurooncol Adv ; 2(1): vdaa163, 2020.
Article em En | MEDLINE | ID: mdl-33392508
BACKGROUND: Glioblastoma remains highly lethal due to its inevitable recurrence. Most of this recurrence is found locally, indicating that postsurgical tumor-initiating cells (TICs) accumulate at the tumor edge. These edge-TICs then generate local recurrence harboring new core lesions. Here, we investigated the clinical significance of the edge-to-core (E-to-C) signature generating glioblastoma recurrence and sought to identify its central mediators. METHODS: First, we examined the association of E-to-C-related expression changes to patient outcome in matched primary and recurrent samples (n = 37). Specifically, we tested whether the combined decrease of the edge-TIC marker PROM1 (CD133) with the increase of the core-TIC marker CD109, representing E-to-C transition during the primary-to-recurrence progression, indicates poorer patient outcome. We then investigated the specific molecular mediators that trigger tumor recurrence driven by the E-to-C progression. Subsequently, the functional and translational significance of the identified molecule was validated with our patient-derived edge-TIC models in vitro and in vivo. RESULTS: Patients exhibiting the CD133low/CD109high signature upon recurrence representing E-to-C transition displayed a strong association with poorer progression-free survival and overall survival among all tested patients. Differential gene expression identified that PLAGL1 was tightly correlated with the core TIC marker CD109 and was linked to shorter patient survival. Experimentally, forced PLAGL1 overexpression enhanced, while its knockdown reduced, glioblastoma edge-derived tumor growth in vivo and subsequent mouse survival, suggesting its essential role in the E-to-C-mediated glioblastoma progression. CONCLUSIONS: E-to-C axis represents an ongoing lethal process in primary glioblastoma contributing to its recurrence, partly in a PLAGL1/CD109-mediated mechanism.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Neurooncol Adv Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Neurooncol Adv Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China